[go: up one dir, main page]

MX2015006973A - Inmunoterapia con agentes de enlace. - Google Patents

Inmunoterapia con agentes de enlace.

Info

Publication number
MX2015006973A
MX2015006973A MX2015006973A MX2015006973A MX2015006973A MX 2015006973 A MX2015006973 A MX 2015006973A MX 2015006973 A MX2015006973 A MX 2015006973A MX 2015006973 A MX2015006973 A MX 2015006973A MX 2015006973 A MX2015006973 A MX 2015006973A
Authority
MX
Mexico
Prior art keywords
binding agents
extracellular domain
bind
immunotherapy
methods
Prior art date
Application number
MX2015006973A
Other languages
English (en)
Inventor
Austin L Gurney
Fumiko Takada Axelrod
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2015006973A publication Critical patent/MX2015006973A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan agentes de enlace que modulan la respuesta inmune. Los agentes de enlace pueden incluir receptores solubles, polipéptidos, y/o anticuerpos. También se divulgan métodos para utilizar los agentes de enlace para el tratamiento de enfermedades tales como el cáncer.
MX2015006973A 2012-12-04 2013-12-04 Inmunoterapia con agentes de enlace. MX2015006973A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261733177P 2012-12-04 2012-12-04
US201361789268P 2013-03-15 2013-03-15
PCT/US2013/073038 WO2014089169A2 (en) 2012-12-04 2013-12-04 Immunotherapy with binding agents

Publications (1)

Publication Number Publication Date
MX2015006973A true MX2015006973A (es) 2015-09-28

Family

ID=50884135

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015006973A MX2015006973A (es) 2012-12-04 2013-12-04 Inmunoterapia con agentes de enlace.

Country Status (17)

Country Link
US (3) US9327014B2 (es)
EP (1) EP2928483A4 (es)
JP (1) JP2016502554A (es)
KR (1) KR20150090919A (es)
CN (1) CN104902913A (es)
AR (1) AR093788A1 (es)
AU (1) AU2013355379B2 (es)
BR (1) BR112015013127A2 (es)
CA (1) CA2892831A1 (es)
HK (1) HK1210964A1 (es)
IL (1) IL239089A0 (es)
MX (1) MX2015006973A (es)
NZ (1) NZ709059A (es)
RU (1) RU2015123032A (es)
TW (1) TW201439115A (es)
WO (1) WO2014089169A2 (es)
ZA (1) ZA201504478B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
EP2858673A4 (en) * 2012-06-06 2016-06-22 Oncomed Pharm Inc BONDING AGENT FOR MODULATING THE HIPPO PATH AND USES THEREOF
JP2016502554A (ja) 2012-12-04 2016-01-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 結合物質を用いた免疫療法
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
BR112016003532A8 (pt) * 2013-08-22 2018-01-30 Council Queensland Inst Medical Res modulação imunorreceptora para tratar o cancer e as infecções virais
MA40437A (fr) * 2014-07-16 2017-05-24 Hoffmann La Roche Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
SG11201701161QA (en) * 2014-08-19 2017-03-30 Merck Sharp & Dohme Anti-tigit antibodies
MA40662B1 (fr) 2014-12-23 2020-12-31 Bristol Myers Squibb Co Anticorps contre tigit
US11319359B2 (en) 2015-04-17 2022-05-03 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
JP7059177B2 (ja) * 2015-09-14 2022-04-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 適応型の表現型を示すｎｋ細胞ならびにその製造方法および使用方法
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
PT3356413T (pt) 2015-10-01 2022-04-04 Potenza Therapeutics Inc Proteínas de ligação a antigénio anti-tigit e métodos de utilização das mesmas
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AU2017228055B2 (en) 2016-03-01 2024-04-04 University Of Rijeka Faculty Of Medicine Antibodies specific to human poliovirus receptor (PVR)
BR112018067458A2 (pt) 2016-03-04 2019-01-02 Abmuno Therapeutics Llc anticorpos para tigit
CN107267454B (zh) * 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
IL262366B2 (en) 2016-04-15 2024-07-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
KR102536850B1 (ko) 2016-04-15 2023-05-26 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
US11331343B2 (en) * 2016-06-29 2022-05-17 Duke University Compositions and methods for activating antigen presenting cells with chimeric poliovirus
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) * 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) * 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
WO2018041120A1 (en) * 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
EP3529361B1 (en) * 2016-10-20 2021-03-24 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CN110662552A (zh) 2016-11-30 2020-01-07 昂科梅德制药有限公司 包含tigit结合剂的癌症治疗方法
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
WO2018195552A1 (en) 2017-04-21 2018-10-25 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
AU2018315432A1 (en) * 2017-08-11 2020-03-26 Blink Biomedical Sas CD96-binding agents as immunomodulators
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
CA3087149A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
MX2020008795A (es) * 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210386829A1 (en) 2018-05-04 2021-12-16 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2019215728A1 (en) 2018-05-09 2019-11-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human nectin4
US11214619B2 (en) 2018-07-20 2022-01-04 Surface Oncology, Inc. Anti-CD112R compositions and methods
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
CN110157686B (zh) * 2019-05-22 2022-06-21 南京惟亚德生物医药有限公司 一种免疫检查点激活免疫共刺激的复制型溶瘤腺病毒及其构建方法和应用
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
TWI764291B (zh) 2019-09-24 2022-05-11 財團法人工業技術研究院 抗tigit抗體及使用方法
ES3053994T3 (en) 2019-09-27 2026-01-28 Glaxosmithkline Ip Dev Ltd Antigen binding proteins
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
WO2021097294A1 (en) * 2019-11-15 2021-05-20 Surface Oncology, Inc. Compositions and methods for immunotherapy
CN114507284B (zh) * 2020-05-09 2023-05-26 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20230277618A1 (en) 2020-08-07 2023-09-07 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
JP2025508076A (ja) 2022-03-08 2025-03-21 アレンティス・セラピューティクス・アクチェンゲゼルシャフト Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2025019828A1 (en) * 2023-07-20 2025-01-23 The General Hospital Corporation Chimeric inhibitory signaling modulators

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US20050037445A1 (en) 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
EP1725585A2 (en) 2004-03-10 2006-11-29 Lonza Ltd Method for producing antibodies
KR20070072510A (ko) 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
JP2008544746A (ja) * 2005-05-12 2008-12-11 ザイモジェネティクス， インコーポレイテッド 免疫応答を調節するための組成物および方法
WO2007053648A2 (en) 2005-10-31 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
AU2007305443B2 (en) 2006-09-29 2012-08-23 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2275431A3 (en) 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
HUE036780T2 (hu) * 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP2016502554A (ja) 2012-12-04 2016-01-28 オンコメッド ファーマシューティカルズ インコーポレイテッド 結合物質を用いた免疫療法

Also Published As

Publication number Publication date
WO2014089169A2 (en) 2014-06-12
CN104902913A (zh) 2015-09-09
AU2013355379B2 (en) 2018-08-09
RU2015123032A (ru) 2017-01-11
EP2928483A2 (en) 2015-10-14
US9833500B2 (en) 2017-12-05
IL239089A0 (en) 2015-07-30
US9327014B2 (en) 2016-05-03
JP2016502554A (ja) 2016-01-28
AU2013355379A1 (en) 2015-07-02
US20160346368A1 (en) 2016-12-01
ZA201504478B (en) 2016-09-28
EP2928483A4 (en) 2016-06-08
KR20150090919A (ko) 2015-08-06
WO2014089169A4 (en) 2014-09-12
US20180214526A1 (en) 2018-08-02
US20140186380A1 (en) 2014-07-03
TW201439115A (zh) 2014-10-16
AR093788A1 (es) 2015-06-24
BR112015013127A2 (pt) 2017-09-26
NZ709059A (en) 2016-11-25
WO2014089169A3 (en) 2014-08-07
CA2892831A1 (en) 2014-06-12
HK1210964A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
NZ709059A (en) Immunotherapy with binding agents
PH12014502406B1 (en) Anti-il-23p19 antibodies
MX347164B (es) Anticuerpos anti-il-36r.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12016501644B1 (en) Binding proteins and methods of use thereof
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12015502087A1 (en) Newcastle disease viruses and uses thereof
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX2013005015A (es) Anticuerpos anti-il-23.
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2014008102A (es) Inmunoglobulinas de dominio variable dual contra receptores.
MX354481B (es) Anticuerpos dkk1 y métodos de uso.
MY158992A (en) Forms of rifaximin and uses thereof
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
MX377618B (es) Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
HK1209639A1 (en) Gpbp-1 inhibition and its therapeutic use